$IAM News
Last published 11h ago
- 11h agoIAMIambic Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoIAMIambic to participate in Jefferies Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Iambic (NASDAQ:IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that Iambic Co-Founder
- 1w agoIAMIambic to participate in Jefferies Global Healthcare ConferenceGlobeNewswireCo-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026
- 3w agoIAMIambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven CancersBusiness WireIAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical development in approximately two years Data presented at ESMO 2026 demonstrates IAM1363 was
- 1mo agoIAMIambic Announces Pricing of Initial Public OfferingBusiness WireIambic Therapeutics, Inc. (Iambic) (NASDAQ:IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering